BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
Art will provide featured remarks to the Harvard Business School on personalized medicine and venture capital on Thursday, March 29 in Boston, MA.
News | 03. 19. 2012
Art will provide featured remarks to the Harvard Business School on personalized medicine and venture capital on Thursday, March 29 in Boston, MA.
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.